 Connection
Thomas Campbell to Zidovudine
This is a "connection" page, showing publications Thomas Campbell has written about Zidovudine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.464 |
|
|
|
-
Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W, Infante R, Rana A, Kumarasamy N, Hakim J, Campbell TB. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015 May-Jun; 16(3):89-99.
Score: 0.121
-
Erlandson KM, Gudza I, Fiorillo S, Ndemera B, Schooley RT, Gwanzura L, Borok M, Campbell TB. Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe. Int J Infect Dis. 2014 Jul; 24:6-10.
Score: 0.112
-
Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DR. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. J Infect Dis. 1993 Aug; 168(2):318-26.
Score: 0.107
-
Erlandson KM, Fiorillo SP, Cardoso SW, Riviere C, Sanchez J, Hakim J, Kumarasamy N, Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation. AIDS Res Hum Retroviruses. 2017 Sep; 33(9):929-934.
Score: 0.035
-
Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 01; 12(4):363-70.
Score: 0.033
-
Shivakoti R, Gupte N, Yang WT, Mwelase N, Kanyama C, Tang AM, Pillay S, Samaneka W, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Semba RD, Christian P, Campbell TB, Gupta A. Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy. Nutrients. 2014 Nov 13; 6(11):5061-78.
Score: 0.029
-
Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014; 19(2):141-7.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|